Generation and characterization of humanized monoclonal antibody against human IFNAR1

QIU Jiwan; KONG Yong; CHEN Wei; XU Lei; CAO Chunjie; CHEN Tao; WU Yiliang

doi:10.11665/j.issn.1000-5048.2024031401

Journal of China Pharmaceutical University > 2024 > 55(3): 404-411. > DOI: 10.11665/j.issn.1000-5048.2024031401

QIU Jiwan, KONG Yong, CHEN Wei, et al. Generation and characterization of humanized monoclonal antibody against human IFNAR1[J]. J China Pharm Univ, 2024, 55(3): 404 − 411. DOI: 10.11665/j.issn.1000-5048.2024031401

Citation:

PDF (2311 KB)

Generation and characterization of humanized monoclonal antibody against human IFNAR1

Qyuns Therapeutics Co., Ltd., Taizhou 225300, China

More Information

Received Date: March 13, 2024
Available Online: June 24, 2024

Graphical Abstract

Abstract

Abstract

Type I interferons play an important role in the pathogenesis of autoimmune diseases such as systemic lupus erythematosus (SLE). Monoclonal antibody shows therapeutic potential by blocking the signaling pathway. This study used recombinant human subunit 1 of the type I interferon receptor (IFNAR1) protein to immunize New Zealand white rabbits, and applied B cell cloning technology to screen and obtain rabbit parental antibodies. After humanization modification, QX006N was obtained. In vitro biological studies showed that QX006N could specifically bind to human IFNAR1 with an affinity of 108 pmol/L, and neutralize the type I interferon signaling pathway and this pathway mediated biological effects. This study provides a solid foundation for the development of antibody drugs targeting the type I interferon signaling pathway for the treatment of SLE.
- B cell cloning,
- humanization,
- rabbit monoclonal antibody,
- IFNAR1,
- type I interferon,
- systemic lupus erythematosus

FullText(HTML)

References (16)

References

[1]	Ramaswamy M, Tummala R, Streicher K, et al. The pathogenesis, molecular mechanisms, and therapeutic potential of the interferon pathway in systemic lupus erythematosus and other autoimmune diseases[J]. Int J Mol Sci, 2021, 22(20): 11286. doi: 10.3390/ijms222011286
[2]	Moll HP, Maier T, Zommer A, et al. The differential activity of interferon-α subtypes is consistent among distinct target genes and cell types[J]. Cytokine, 2011, 53(1): 52-59. doi: 10.1016/j.cyto.2010.09.006
[3]	Peng L, Oganesyan V, Wu H, et al. Molecular basis for antagonistic activity of anifrolumab, an anti-interferon-α receptor 1 antibody[J]. MAbs, 2015, 7(2): 428-439. doi: 10.1080/19420862.2015.1007810
[4]	González-Navajas JM, Lee J, David M, et al. Immunomodulatory functions of type I interferons[J]. Nat Rev Immunol, 2012, 12(2): 125-135. doi: 10.1038/nri3133
[5]	Jiang J, Zhao M, Chang C, et al. Type I interferons in the pathogenesis and treatment of autoimmune diseases[J]. Clin Rev Allergy Immunol, 2020, 59(2): 248-272. doi: 10.1007/s12016-020-08798-2
[6]	Rönnblom L, Leonard D. Interferon pathway in SLE: one key to unlocking the mystery of the disease[J]. Lupus Sci Med, 2019, 6(1): e000270. doi: 10.1136/lupus-2018-000270
[7]	Crow MK, Olferiev M, Kirou KA. Type I interferons in autoimmune disease[J]. Annu Rev Pathol, 2019, 14: 369-393. doi: 10.1146/annurev-pathol-020117-043952
[8]	Kalunian KC, Merrill JT, Maciuca R, et al. A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE)[J]. Ann Rheum Dis, 2016, 75(1): 196-202. doi: 10.1136/annrheumdis-2014-206090
[9]	Anderson E, Furie R. Anifrolumab in systemic lupus erythematosus: current knowledge and future considerations[J]. Immunotherapy, 2020, 12(5): 275-286. doi: 10.2217/imt-2020-0017
[10]	Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study[J]. Ann Rheum Dis, 2016, 75(11): 1909-1916. doi: 10.1136/annrheumdis-2015-208562
[11]	Kaplon H, Chenoweth A, Crescioli S, et al. Antibodies to watch in 2022[J]. MAbs, 2022, 14(1): 2014296. doi: 10.1080/19420862.2021.2014296
[12]	Deeks ED. Anifrolumab: first approval[J]. Drugs, 2021, 81(15): 1795-1802. doi: 10.1007/s40265-021-01604-z
[13]	Piehler J, Thomas C, Garcia KC, et al. Structural and dynamic determinants of type I interferon receptor assembly and their functional interpretation[J]. Immunol Rev, 2012, 250(1): 317-334. doi: 10.1111/imr.12001
[14]	Weber J, Peng HY, Rader C. From rabbit antibody repertoires to rabbit monoclonal antibodies[J]. Exp Mol Med, 2017, 49(3): e305. doi: 10.1038/emm.2017.23
[15]	Markham A. Brolucizumab: first approval[J]. Drugs, 2019, 79(18): 1997-2000. doi: 10.1007/s40265-019-01231-9
[16]	Dhillon S. Eptinezumab: first approval[J]. Drugs, 2020, 80(7): 733-739. doi: 10.1007/s40265-020-01300-4

[1]	ZHANG Zhixing, DENG Hua, TANG Yun. Applications and challenges of artificial intelligence in the development of anticancer peptides[J]. Journal of China Pharmaceutical University, 2024, 55(3): 347-356. DOI: 10.11665/j.issn.1000-5048.2024040201
[2]	HU Zi’ang, GAO Liming, YU Wenying. Advances in the application of artificial intelligence in nucleic acid drug development[J]. Journal of China Pharmaceutical University, 2024, 55(3): 335-346. DOI: 10.11665/j.issn.1000-5048.2024033101
[3]	ZENG Hao, WU Guozhen, ZOU Wuxin, WANG Zhe, SONG Jianfei, SHI Hui, WANG Xiaojian, HOU Tingjun, DENG Yafeng. Optimization of Menin inhibitors based on artificial intelligence-driven molecular factory technology[J]. Journal of China Pharmaceutical University, 2024, 55(3): 326-334. DOI: 10.11665/j.issn.1000-5048.2024040904
[4]	JIANG Zhengyu, YOU Qidong. Assistance of artificial intelligence in new drug development[J]. Journal of China Pharmaceutical University, 2024, 55(3): 281-283. DOI: 10.11665/j.issn.1000-5048.2024060302
[5]	XUE Feng, FENG Shuo, LI Jing. Application and prospect of artificial intelligence in antimicrobial peptides screening[J]. Journal of China Pharmaceutical University, 2023, 54(3): 314-322. DOI: 10.11665/j.issn.1000-5048.2023030901
[6]	GU Zhihao, GUO Wenhao, YAO Hequan, LI Xuanyi, LIN Kejiang. Research progress of the screening and generation of lead compounds based on artificial intelligence model[J]. Journal of China Pharmaceutical University, 2023, 54(3): 294-304. DOI: 10.11665/j.issn.1000-5048.2023042201
[7]	YU Zehao, ZHANG Leiming, ZHANG Mengna, DAI Zhiqi, PENG Chengbin, ZHENG Siming. Artificial intelligence-based drug development: current progress and future challenges[J]. Journal of China Pharmaceutical University, 2023, 54(3): 282-293. DOI: 10.11665/j.issn.1000-5048.2023041003
[8]	WANG Chao, XIAO Fu, LI Miaozhu, PAN Ying, DING Xiao, REN Feng, ZHAVORONKOV Alex, WANG Yazhou. Application progress of artificial intelligence in the screening and identification of drug targets[J]. Journal of China Pharmaceutical University, 2023, 54(3): 269-281. DOI: 10.11665/j.issn.1000-5048.2023041102
[9]	YAN Fangrong. Application and advance of artificial intelligence in biomedical field[J]. Journal of China Pharmaceutical University, 2023, 54(3): 263-268. DOI: 10.11665/j.issn.1000-5048.2023030304
[10]	Application of Genechip Technology in Drug Discovery and Development[J]. Journal of China Pharmaceutical University, 2001, (2): 1-6.

Cited By

Cited by

Periodical cited type(2)

1.	冯馨锐，吴韦铷，张晓丽，杨忠，邓有才，毕清华. 人工智能在临床血液学检验教学中的应用. 中华检验医学杂志. 2025(02): 286-291 .
2.	陈雨欣，付慧，赵熠，徐芳芳，沈甫明. 主动脉夹层发病机制的研究进展. 同济大学学报(医学版). 2025(02): 292-299 .

Other cited types(0)

Get Citation

PDF

XML

Article views (82) PDF downloads (18) Cited by(2)

Turn off MathJax

Article Contents

Abstract

References

Generation and characterization of humanized monoclonal antibody against human IFNAR1